Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma

摘要: Platinum-based chemotherapy in combination with immune-checkpoint inhibitors is the current standard of care for patients advanced lung adenocarcinoma (LUAD). However, tumor progression evolves most cases. Therefore, predictive biomarkers are needed better patient stratification and identification new therapeutic strategies, including enhancing efficacy chemotoxic agents. Here, we hypothesized that discoidin domain receptor 1 (DDR1) may be both a factor chemoresistance LUAD potential target positively selected resistant cells. By using biopsies from LUAD, KRAS-mutant cell lines, vivo genetically engineered KRAS-driven mouse models, evaluated role DDR1 context treatment. We found upregulated during vitro vivo. Moreover, analysis cohort suggested high levels pretreatment correlated poor response to chemotherapy. Additionally, showed combining inhibition prompted synergistic effect enhanced death tumors Collectively, this study suggests as prognostic biomarker, potentially improving LUAD.